Bal Pharma Q3FY26 Unaudited Results: Net Profit ₹194.62 Lakhs Standalone, ₹177.99 Lakhs Consolidated
Bal Pharma reported unaudited standalone net profit of ₹194.62 Lakhs and consolidated net profit of ₹177.99 Lakhs for Q3FY26. Revenue from operations was ₹8,749.48 Lakhs (standalone) and ₹8,768.97 Lakhs (consolidated). Auditors issued an unmodified opinion.
The announcement of quarterly financial results is material information for investors and stakeholders, impacting investment decisions and company valuation. The results themselves, showing profitability, are of moderate importance.
The financial results for the quarter are reported, showing a net profit for both standalone and consolidated statements. While the results are positive, they do not indicate a significant deviation or exceptional performance that would warrant a 'POSITIVE' sentiment. The unmodified auditor's opinion is standard.
Bal Pharma Limited announced its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025, following a Board of Directors meeting held on February 11, 2026.
For the quarter ended December 31, 2025, the company reported a standalone net profit of ₹194.62 Lakhs. The revenue from operations stood at ₹8,749.48 Lakhs. The standalone total income was ₹8,783.99 Lakhs, with total expenses at ₹8,589.37 Lakhs.
On a consolidated basis, Bal Pharma Limited reported a net profit attributable to equity holders of ₹177.99 Lakhs for the same quarter. The consolidated revenue from operations was ₹8,768.97 Lakhs, and the total consolidated income was ₹8,801.59 Lakhs, with total consolidated expenses at ₹8,622.53 Lakhs.
The statutory auditors, SSJNB & Co, have issued a limited review report with an unmodified opinion on both the standalone and consolidated financial results.
What to do with a filing like this
Bal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bal Pharma Limited. Read the original for the full detail.